Compare CASY & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CASY | PODD |
|---|---|---|
| Founded | 1959 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Medical/Dental Instruments |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.0B | 22.1B |
| IPO Year | N/A | 2007 |
| Metric | CASY | PODD |
|---|---|---|
| Price | $564.76 | $296.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 19 |
| Target Price | ★ $576.20 | $359.00 |
| AVG Volume (30 Days) | 273.6K | ★ 751.9K |
| Earning Date | 12-09-2025 | 11-06-2025 |
| Dividend Yield | ★ 0.40% | N/A |
| EPS Growth | ★ 13.46 | N/A |
| EPS | ★ 15.58 | 3.45 |
| Revenue | ★ $16,410,268,000.00 | $2,521,800,000.00 |
| Revenue This Year | $11.07 | $32.55 |
| Revenue Next Year | $5.86 | $20.39 |
| P/E Ratio | ★ $36.39 | $85.86 |
| Revenue Growth | 8.74 | ★ 27.11 |
| 52 Week Low | $372.09 | $230.05 |
| 52 Week High | $573.76 | $354.88 |
| Indicator | CASY | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 56.82 | 37.28 |
| Support Level | $554.09 | $303.20 |
| Resistance Level | $573.76 | $317.34 |
| Average True Range (ATR) | 12.96 | 13.25 |
| MACD | 0.95 | -3.48 |
| Stochastic Oscillator | 77.34 | 0.63 |
Casey's General Stores Inc serves as convenience store chain with its 2,900 locations, positioned in the Midwest United States. About half of Casey's stores are located in rural towns with populations under 5,000. While fueling stations serve as a key traffic driver, about two-thirds of the company's gross profit stems from in-store sales of grocery items, prepared meals, and general merchandise. Casey's owns more than 90% of its stores and operates the majority of its warehousing and distribution processes internally.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.